New cell therapy aims to stop blood cancers from coming back

NCT ID NCT06704152

First seen Sep 30, 2025 · Last updated May 24, 2026 · Updated 34 times

Summary

This early-phase trial tests a new cell therapy called BSB-1001 in 38 adults with high-risk blood cancers (AML, ALL, or MDS) who have had a stem cell transplant. The therapy uses specially modified immune cells to target and kill cancer cells that may remain, with the goal of preventing relapse. The main focus is on safety, including side effects and graft-versus-host disease, while also checking if the treatment helps keep cancer away.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML, ADULT RECURRENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • City of Hope National Medical Center

    RECRUITING

    Duarte, California, 91010, United States

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

  • The Ohio State University

    RECRUITING

    Columbus, Ohio, 43210, United States

  • University of Michigan

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

  • University of Minnesota

    RECRUITING

    Minneapolis, Minnesota, 55455, United States

  • Washington University at St Louis

    RECRUITING

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.